Molecular underpinnings of enzalutamide resistance

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men.
• Androgen receptor (AR) signaling blockade, using drugs like enzalutamide, is a key treatment for advanced PCa.
• Treatment resistance eventually develops, leading to lethal disease with no cure.

Purpose of the Study:

• To review the molecular mechanisms underlying enzalutamide resistance in prostate cancer.
• To bridge preclinical and clinical research on overcoming treatment resistance.
• To identify novel therapeutic strategies for advanced, lethal prostate cancer.

Main Methods:

• Literature review of preclinical and clinical studies on enzalutamide resistance.
• Analysis of molecular pathways involved in treatment resistance.
• Synthesis of current research on therapeutic interventions.

Main Results:

• Enzalutamide resistance is driven by complex molecular alterations.
• Understanding these mechanisms is crucial for developing effective treatments.
• Several novel therapeutic strategies are emerging from research.

Conclusions:

• Enzalutamide resistance remains a significant challenge in advanced prostate cancer management.
• Further research integrating preclinical findings with clinical applications is needed.
• Targeting resistance mechanisms offers hope for improved outcomes in lethal PCa.